Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann‐Lii ChengNational Taiwan University Hospital, Taipei, TaiwanYoon‐Koo KangASAN Medical Centre, Songpa-gu, Seoul, Republic of KoreaZhendong ChenFirst Affiliated Hospital of Anhui Medical University, Hefei, ChinaChao-Jung TsaoChi Mei Medical Centre, Liou Ying Campus, Tainan, TaiwanShukui QinNanjing Bayi Hospital, Nanjing, ChinaJun Suk KimKorea University Guro Hospital, Seoul, Republic of KoreaRongcheng LuoNanfang Medical University Nanfang Hospital, Guangzhou, ChinaJifeng FengCancer Hospital of Jiangsu Province, Nanjing, ChinaSheng‐Long YeZhongshan Hospital, Fudan University, Shanghai, ChinaTsai‐Sheng YangChang Gung Memorial Hospital, Tao-Yuan, TaiwanJianming XuAffiliated Hospital of Academy of Military Medical Sciences, Beijing, ChinaYan SunCancer Institute and Hospital of CAMS, Beijing, ChinaHoujie LiangSouthwest Hospital of Third Military Medical University, Chongqing, ChinaJiwei LiuFirst Affiliated Hospital of Dalian Medical University, Dalian, ChinaJiejun WangShanghai Changzheng Hospital, Shanghai, ChinaWon Young TakKyungpook National University Hospital, Daegu, Republic of KoreaHongming PanSir Run Run Shaw Hospital, Zhejiang, ChinaK. BurockBayer Schering Pharma, Wuppertal, GermanyJessie ZouBayer Schering Pharma, Shanghai, ChinaD. VoliotisBayer Healthcare, Montville, NJ, USAZhongzhen GuanSun Yat-sen University Cancer Centre, Guangzhou, China
2008en
ABI
Abstract
No abstract available.
Identifiers
Citations and references
Cited by 20 references